We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Clinical-Grade Recombinant Proteins for Cell Therapy

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "Clinical-Grade Recombinant Proteins for Cell Therapy"

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:

AMSBIO announces the launch of its StemFit Purotein® range of high purity, high activity recombinant proteins for cell therapy applications.

Continued expansion of cell therapy applications across healthcare and the life sciences is driving a rapidly increasing need for clinically applicable ancillary materials. A key requirement is for recombinant proteins, such as growth factors and cytokines. This demand for clinically applicable recombinant proteins places stringent requirements on product quality, lot-to-lot consistency, and compliance with all relevant laws and regulations.

All StemFit Purotein® products are designed and manufactured under a strict animal-free protocol** which minimizes risk of virus contamination and ensures high lot-to-lot consistency. Manufactured using a streamlined (optionally GMP compliant) production and purification process results in recombinant proteins of the highest purity and quality while maintaining affordable prices. The StemFit Purotein® range includes recombinant proteins that play key roles in differentiation of ES and iPS cells into liver, pancreas, kidney, heart, blood, and immune cells. Beneficially, StemFit Purotein® products are supplied in a ‘ready-to-use’ frozen liquid form which eliminates the time-consuming process of reconstitution while ensuring consistent results.

Purotein® products are fully compatible with the StemFit® range of xeno-free, chemically defined media which is proven to effectively maintain induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) under feeder-free conditions during the reprogramming, expansion and differentiation phases of stem cell culture and growth medium.